LRRC40

Summary

LRRC40 (leucine rich repeat containing 40, HGNC:26004) is a protein-coding gene on chromosome 1p31.1, encoding Leucine-rich repeat-containing protein 40 (Q9H9A6).

Predicted to be involved in intracellular signal transduction. Located in membrane.

Source: NCBI Gene 55631 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 89 total
• Phenotypes (HPO): 1
• Druggable target: yes
• MANE Select transcript: NM_017768

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26004
Approved symbol	LRRC40
Name	leucine rich repeat containing 40
Location	1p31.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ20331
Ensembl gene	ENSG00000066557
Ensembl biotype	protein_coding
Entrez	55631

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 10 protein_coding

ENST00000370952, ENST00000861873, ENST00000861874, ENST00000861875, ENST00000920865, ENST00000920866, ENST00000920867, ENST00000920868, ENST00000963788, ENST00000963789

RefSeq mRNA: 1 — MANE Select: NM_017768 NM_017768

CCDS: CCDS646

Canonical transcript exons

ENST00000370952 — 15 exons

Exon	Start	End
ENSE00000473737	70175810	70175982
ENSE00000774596	70148487	70148672
ENSE00000774597	70151128	70151205
ENSE00000774605	70152433	70152543
ENSE00000774610	70155689	70155796
ENSE00000774614	70159330	70159438
ENSE00000774621	70173465	70173510
ENSE00000774633	70173622	70173709
ENSE00000798451	70178851	70178993
ENSE00000798452	70184785	70184914
ENSE00000903855	70181086	70181209
ENSE00000956617	70189092	70189273
ENSE00000956618	70187265	70187338
ENSE00001453981	70144805	70145905
ENSE00001453984	70205390	70205579

Expression profiles

Bgee: expression breadth ubiquitous, 283 present calls, max score 95.45.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.8654 / max 270.0191, expressed in 1804 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
12799	23.7850	1804
12798	0.0804	26

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
jejunal mucosa	UBERON:0000399	95.45	gold quality
oocyte	CL:0000023	94.24	gold quality
secondary oocyte	CL:0000655	94.18	gold quality
endothelial cell	CL:0000115	93.61	gold quality
jejunum	UBERON:0002115	93.18	gold quality
Brodmann (1909) area 23	UBERON:0013554	92.79	gold quality
cortical plate	UBERON:0005343	91.87	gold quality
embryo	UBERON:0000922	91.37	gold quality
oral cavity	UBERON:0000167	91.19	gold quality
synovial joint	UBERON:0002217	90.72	gold quality
cerebellar vermis	UBERON:0004720	90.62	gold quality
skin of hip	UBERON:0001554	90.59	gold quality
superficial temporal artery	UBERON:0001614	90.59	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	90.55	gold quality
hair follicle	UBERON:0002073	90.39	gold quality
upper leg skin	UBERON:0004262	90.15	gold quality
pons	UBERON:0000988	89.80	gold quality
ganglionic eminence	UBERON:0004023	89.79	gold quality
heart right ventricle	UBERON:0002080	89.70	gold quality
trigeminal ganglion	UBERON:0001675	89.69	gold quality
parietal pleura	UBERON:0002400	89.53	gold quality
cauda epididymis	UBERON:0004360	89.52	gold quality
biceps brachii	UBERON:0001507	89.36	gold quality
ventricular zone	UBERON:0003053	89.11	gold quality
calcaneal tendon	UBERON:0003701	89.06	gold quality
mammary duct	UBERON:0001765	89.00	gold quality
penis	UBERON:0000989	88.89	gold quality
duodenum	UBERON:0002114	88.88	gold quality
epithelium of nasopharynx	UBERON:0001951	88.78	gold quality
superior vestibular nucleus	UBERON:0007227	88.74	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	4.12

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

75 targeting LRRC40, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-369-3P	99.85	70.52	2264

Literature-anchored findings (GeneRIF, showing 1)

• PLXNA2 and LRRC40 as candidate genes in autism spectrum disorder. (PMID:33749153)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	lrrc40	ENSDARG00000017708
mus_musculus	Lrrc40	ENSMUSG00000063052
rattus_norvegicus	Lrrc40	ENSRNOG00000011555

Paralogs (31): LRRC7 (ENSG00000033122), PHLPP2 (ENSG00000040199), LRCH4 (ENSG00000077454), PHLPP1 (ENSG00000081913), SHOC2 (ENSG00000108061), ERBIN (ENSG00000112851), LRRC39 (ENSG00000122477), LRCH2 (ENSG00000130224), LRCH1 (ENSG00000136141), LRRC8A (ENSG00000136802), LRRC1 (ENSG00000137269), MFHAS1 (ENSG00000147324), LRRC27 (ENSG00000148814), LRRK1 (ENSG00000154237), LRRC58 (ENSG00000163428), LRRC2 (ENSG00000163827), LRRC18 (ENSG00000165383), LRRC28 (ENSG00000168904), LRRC8E (ENSG00000171017), LRRC8C (ENSG00000171488), LRRC8D (ENSG00000171492), PIDD1 (ENSG00000177595), SCRIB (ENSG00000180900), LRCH3 (ENSG00000186001), LRRIQ4 (ENSG00000188306), LRRC8B (ENSG00000197147), LRRC10 (ENSG00000198812), LRRC10B (ENSG00000204950), LRRC30 (ENSG00000206422), LRRC69 (ENSG00000214954), LRRD1 (ENSG00000240720)

Protein

Protein identifiers

Leucine-rich repeat-containing protein 40 — Q9H9A6 (reviewed: Q9H9A6)

All UniProt accessions (2): Q9H9A6, A0A140VJN3

RefSeq proteins (1): NP_060238* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR050333	SLRP	Family

Pfam: PF13855

UniProt features (25 total): repeat 20, sequence variant 2, chain 1, modified residue 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H9A6-F1	83.35	0.42

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 71

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 124 (showing top): MODULE_256, DODD_NASOPHARYNGEAL_CARCINOMA_UP, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, ZHANG_BREAST_CANCER_PROGENITORS_UP, MOREAUX_MULTIPLE_MYELOMA_BY_TACI_DN, MARSON_BOUND_BY_E2F4_UNSTIMULATED, HAMAI_APOPTOSIS_VIA_TRAIL_UP, COLINA_TARGETS_OF_4EBP1_AND_4EBP2, FOSTER_KDM1A_TARGETS_DN, PDGF_ERK_DN.V1_DN, CREB3L4_TARGET_GENES, DIDO1_TARGET_GENES, DLX4_TARGET_GENES, HMG20B_TARGET_GENES, HOXB4_TARGET_GENES

GO Biological Process (1): intracellular signal transduction (GO:0035556)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular anatomical structure	1
signal transduction	1
binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1505 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LRRC40	GML	Q99445	609
LRRC40	SMIM12	Q96EX1	555
LRRC40	TUBB8	Q3ZCM7	524
LRRC40	SHISA4	Q96DD7	512
LRRC40	CLEC2L	P0C7M8	512
LRRC40	TEX2	Q8IWB9	504
LRRC40	MNMIP1	A4FU49	503
LRRC40	BTBD8	Q5XKL5	498
LRRC40	NAIF1	Q69YI7	487
LRRC40	ZC3H8	Q8N5P1	480
LRRC40	CLIP1	P30622	474
LRRC40	MYL4	P11783	463
LRRC40	KCTD19	Q17RG1	462
LRRC40	SPEF2	Q9C093	460
LRRC40	NABP2	Q9BQ15	456

IntAct

87 interactions, top by confidence:

A	B	Type	Score
CNOT6L	CNOT1	psi-mi:“MI:0914”(association)	0.810
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
LRRC57	MACIR	psi-mi:“MI:0914”(association)	0.640
LRRC40	PGK2	psi-mi:“MI:0915”(physical association)	0.560
DNAL1	LRRC40	psi-mi:“MI:0915”(physical association)	0.560
LRRC40	PGK2	psi-mi:“MI:0914”(association)	0.560
VASN	AP3B1	psi-mi:“MI:0914”(association)	0.530
SKP2	DPYSL4	psi-mi:“MI:0914”(association)	0.530
USP47	DENR	psi-mi:“MI:0914”(association)	0.530
LRIG1	LRIG2	psi-mi:“MI:0914”(association)	0.530
CNPY3	SELENOT	psi-mi:“MI:0914”(association)	0.530
BAG2	HGS	psi-mi:“MI:0914”(association)	0.530
LRRC27	HMOX1	psi-mi:“MI:0914”(association)	0.530
CNPY3	LRIG2	psi-mi:“MI:0914”(association)	0.530
KLHL15	LRRC40	psi-mi:“MI:0915”(physical association)	0.400
	LRRC40	psi-mi:“MI:0915”(physical association)	0.400
JUN	TPM3	psi-mi:“MI:0914”(association)	0.350
HSCB	RBP5	psi-mi:“MI:0914”(association)	0.350
LRRK2		psi-mi:“MI:0914”(association)	0.350
GTF2E2	UBA6	psi-mi:“MI:0914”(association)	0.350
KERA	VWA8	psi-mi:“MI:0914”(association)	0.350
ISLR	DDX11L8	psi-mi:“MI:0914”(association)	0.350
AMTN	NARS1	psi-mi:“MI:0914”(association)	0.350

BioGRID (113): LRRC40 (Affinity Capture-MS), LRRC40 (Affinity Capture-MS), LRRC40 (Affinity Capture-MS), LRRC40 (Affinity Capture-MS), LRRC40 (Affinity Capture-MS), LRRC40 (Affinity Capture-MS), LRRC40 (Affinity Capture-MS), LRRC40 (Affinity Capture-MS), LRRC40 (Affinity Capture-MS), LRRC40 (Affinity Capture-MS), LRRC40 (Affinity Capture-MS), LRRC40 (Affinity Capture-MS), LRRC40 (Affinity Capture-MS), LRRC40 (Affinity Capture-MS), PGK2 (Affinity Capture-MS)

ESM2 similar proteins: A6QLV3, A7SFP1, A8XWW4, B0W6M9, B3LWU3, B3P3E8, B4IBI9, B4JTV9, B4LXW1, B4N9T4, B4PU77, B4QVR7, B5DX45, B6CZ61, B9F655, O35125, O88520, Q1L8Y7, Q22875, Q32KP2, Q4R3P6, Q4V8I7, Q53EV4, Q5F4C4, Q5FVI3, Q5GIG6, Q5M8G4, Q5RAV5, Q5RFE9, Q5ZLN0, Q6AYI5, Q6DHL5, Q6GPJ5, Q6INV3, Q6P1C6, Q6UXM1, Q6ZVD8, Q7SXW3, Q7Z4L9, Q80VQ1

Diamond homologs: A8WHP9, B0M0P8, B1H234, D3ZTV3, F1NUK7, F4J7T6, O02678, O35103, O35367, O42235, O43155, O46377, O46378, O46379, O46390, O46403, O60938, O62702, O77742, O81825, O94769, P0DV53, P12024, P13605, P19879, P20774, P21809, P21810, P28653, P28654, P47853, P50608, P50609, P51884, P51885, P51886, P51887, P51890, P59383, Q05443

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

89 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	59
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2717 predictions. Top by Δscore:

Variant	Effect	Δscore
1:70145902:TGTT:T	acceptor_gain	1.0000
1:70145906:C:CC	acceptor_gain	1.0000
1:70151201:TGTTC:T	acceptor_gain	1.0000
1:70151205:CCTAA:C	acceptor_loss	1.0000
1:70151206:C:CC	acceptor_gain	1.0000
1:70151206:C:CG	acceptor_loss	1.0000
1:70151211:T:TC	acceptor_gain	1.0000
1:70152428:AATAC:A	donor_loss	1.0000
1:70152429:ATACC:A	donor_loss	1.0000
1:70152430:TA:T	donor_loss	1.0000
1:70152431:A:T	donor_loss	1.0000
1:70152432:C:CG	donor_loss	1.0000
1:70152539:CCATC:C	acceptor_gain	1.0000
1:70152540:CATC:C	acceptor_gain	1.0000
1:70152540:CATCC:C	acceptor_gain	1.0000
1:70152542:TC:T	acceptor_gain	1.0000
1:70152543:CC:C	acceptor_gain	1.0000
1:70152544:C:CC	acceptor_gain	1.0000
1:70155792:TATCA:T	acceptor_gain	1.0000
1:70155793:ATCA:A	acceptor_gain	1.0000
1:70155794:TCA:T	acceptor_gain	1.0000
1:70155795:CA:C	acceptor_gain	1.0000
1:70155795:CAC:C	acceptor_gain	1.0000
1:70155797:C:CC	acceptor_gain	1.0000
1:70173616:ACTT:A	donor_loss	1.0000
1:70173618:TTAC:T	donor_loss	1.0000
1:70173619:TACAC:T	donor_loss	1.0000
1:70173620:A:AC	donor_gain	1.0000
1:70173621:C:CT	donor_gain	1.0000
1:70173621:CA:C	donor_gain	1.0000

AlphaMissense

3955 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:70189165:A:G	L87P	0.998
1:70205419:A:G	L41S	0.998
1:70187274:A:G	L133P	0.997
1:70189096:A:G	L110P	0.996
1:70189190:A:G	W79R	0.996
1:70189190:A:T	W79R	0.996
1:70189261:A:T	V55D	0.996
1:70173655:A:C	N344K	0.995
1:70173655:A:T	N344K	0.995
1:70175821:A:C	N322K	0.995
1:70175821:A:T	N322K	0.995
1:70175831:A:G	L319P	0.995
1:70187327:A:C	N115K	0.995
1:70187327:A:T	N115K	0.995
1:70189174:A:G	L84S	0.995
1:70189188:C:A	W79C	0.995
1:70189188:C:G	W79C	0.995
1:70205425:C:T	G39D	0.995
1:70145884:A:C	N575K	0.994
1:70145884:A:T	N575K	0.994
1:70148544:A:G	L549P	0.994
1:70175962:G:C	N275K	0.994
1:70175962:G:T	N275K	0.994
1:70189149:A:C	N92K	0.994
1:70189149:A:T	N92K	0.994
1:70148505:C:T	G562D	0.993
1:70148534:A:C	N552K	0.993
1:70148534:A:T	N552K	0.993
1:70175837:A:G	L317P	0.993
1:70189096:A:T	L110H	0.993

dbSNP variants (sampled 300 via entrez): RS1000105759 (1:70189781 G>A), RS1000179538 (1:70176399 G>A), RS1000237886 (1:70170577 T>A,C), RS1000317176 (1:70161753 G>C), RS1000462542 (1:70179980 G>A), RS1000561013 (1:70189410 A>T), RS1000596241 (1:70184167 T>C), RS1000644204 (1:70163135 G>A), RS1000651635 (1:70183854 C>G), RS1000747202 (1:70187328 T>C), RS1000784854 (1:70177817 T>C), RS1000810779 (1:70198603 G>C), RS1000882919 (1:70198261 T>C), RS1000901219 (1:70149095 T>C,G), RS1000901585 (1:70177452 C>T)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (1): autism (MONDO:0005260)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5724637 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

47 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
perfluorooctane sulfonic acid	decreases expression	2
Air Pollutants	decreases expression, increases abundance	2
Valproic Acid	decreases expression, affects cotreatment, increases expression	2
aristolochic acid I	decreases expression	1
dicrotophos	decreases expression	1
2,4,6-tribromophenol	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
decabromobiphenyl ether	decreases expression	1
methylparaben	decreases expression	1
sodium arsenite	decreases expression	1
tetrabromobisphenol A	decreases expression	1
manganese chloride	increases abundance, increases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
epigallocatechin gallate	decreases expression, affects cotreatment	1
2,3,5-(triglutathion-S-yl)hydroquinone	increases ADP-ribosylation	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
ICG 001	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
bisphenol S	decreases methylation	1
jinfukang	decreases expression	1
LDN 193189	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Acetaminophen	decreases expression	1
Arsenicals	increases methylation	1
Coal	decreases expression, increases abundance	1
Doxorubicin	decreases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1

ChEMBL screening assays

6 unique, capped per target: 6 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5697385	Binding	Inhibition of LRRC40 (unknown origin) assessed as fold change at 10 uM incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. — Nature

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00211796	PHASE4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	PHASE4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	PHASE4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	PHASE4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	PHASE4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	PHASE4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00036231	PHASE3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	PHASE3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	PHASE3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	PHASE3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	PHASE3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	PHASE3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	PHASE3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms